PL353063A1 - Preparat farmaceutyczny o polepszonej rozpuszczalności i wchłanialności po podaniu doustnie, zawierający pochodną benzamidową - Google Patents

Preparat farmaceutyczny o polepszonej rozpuszczalności i wchłanialności po podaniu doustnie, zawierający pochodną benzamidową

Info

Publication number
PL353063A1
PL353063A1 PL00353063A PL35306300A PL353063A1 PL 353063 A1 PL353063 A1 PL 353063A1 PL 00353063 A PL00353063 A PL 00353063A PL 35306300 A PL35306300 A PL 35306300A PL 353063 A1 PL353063 A1 PL 353063A1
Authority
PL
Poland
Prior art keywords
histone deacetylase
deacetylase inhibitor
inhibitor activity
benzamide
formulation
Prior art date
Application number
PL00353063A
Other languages
English (en)
Other versions
PL201274B1 (pl
Inventor
Masahiko Ishibashi
Masahiro Sakabe
Ikuo Sakai
Tsuneji Suzuki
Tomoyuki Ando
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL353063A1 publication Critical patent/PL353063A1/pl
Publication of PL201274B1 publication Critical patent/PL201274B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PL353063A 1999-08-30 2000-08-29 Lek przeciwnowotworowy PL201274B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24244499A JP2001081031A (ja) 1999-08-30 1999-08-30 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
PCT/EP2000/008421 WO2001016106A1 (en) 1999-08-30 2000-08-29 Benzamide formulation with histone deacetylase inhibitor activity

Publications (2)

Publication Number Publication Date
PL353063A1 true PL353063A1 (pl) 2003-10-06
PL201274B1 PL201274B1 (pl) 2009-03-31

Family

ID=17089193

Family Applications (1)

Application Number Title Priority Date Filing Date
PL353063A PL201274B1 (pl) 1999-08-30 2000-08-29 Lek przeciwnowotworowy

Country Status (32)

Country Link
US (1) US6638530B1 (pl)
EP (1) EP1208086B1 (pl)
JP (2) JP2001081031A (pl)
KR (1) KR100712640B1 (pl)
CN (1) CN1147472C (pl)
AR (1) AR025434A1 (pl)
AT (1) ATE318258T1 (pl)
AU (1) AU773617B2 (pl)
BG (1) BG65544B1 (pl)
BR (1) BR0013648A (pl)
CA (1) CA2382886C (pl)
CZ (1) CZ301737B6 (pl)
DE (1) DE60026144T2 (pl)
DK (1) DK1208086T3 (pl)
EE (1) EE05063B1 (pl)
ES (1) ES2259289T3 (pl)
HK (1) HK1046277B (pl)
HR (1) HRP20020182B1 (pl)
HU (1) HUP0203330A3 (pl)
IL (2) IL148357A0 (pl)
MX (1) MXPA02002090A (pl)
NO (1) NO322532B1 (pl)
NZ (1) NZ517520A (pl)
PL (1) PL201274B1 (pl)
PT (1) PT1208086E (pl)
RU (1) RU2260428C2 (pl)
SI (1) SI1208086T1 (pl)
SK (1) SK287252B6 (pl)
TW (1) TWI268778B (pl)
UA (1) UA72541C2 (pl)
WO (1) WO2001016106A1 (pl)
ZA (1) ZA200201424B (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
WO2002078669A1 (fr) * 2001-03-30 2002-10-10 Takeda Chemical Industries, Ltd. Solutions medicinales
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CA2465978C (en) * 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (en) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
AU2003211362A1 (en) * 2002-02-21 2003-09-09 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
MXPA04008577A (es) 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
DE10233412A1 (de) * 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN100455564C (zh) * 2003-09-12 2009-01-28 深圳微芯生物科技有限责任公司 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
CN1882529A (zh) * 2003-09-24 2006-12-20 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
AU2004276337B2 (en) * 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
CA2552279C (en) 2003-12-02 2014-07-15 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
EP1697538A1 (en) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying histone deacetylase inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007017728A2 (en) * 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
WO2008123395A1 (ja) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
CA2706750A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2009140164A1 (en) * 2008-05-16 2009-11-19 Chipscreen Biosciences Ltd. 6-aminonicotinamide derivatives as potent and selective histone deacetylase inhibitors
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
CN103172540B (zh) * 2013-03-18 2015-07-01 潍坊博创国际生物医药研究院 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
MX2019000342A (es) * 2016-07-08 2019-09-04 Ranedis Pharmaceuticals Llc Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.
WO2018222572A1 (en) * 2017-06-01 2018-12-06 Warner Babcock Institute For Green Chemistry, Llc Non-covalent derivatives and methods of treatment
WO2018226939A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
BR112021021232A2 (pt) 2019-04-25 2021-12-21 Fuji Pharma Co Ltd Preparação farmacêutica na forma de grânulos, preparação, método de produção de uma preparação farmacêutica e métodos para a produção de comprimidos e para a produção de cápsulas
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
CN115734782A (zh) 2020-10-28 2023-03-03 株式会社基诺制药 用于预防或治疗病毒性阴道周边部疾病的医药组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT956865E (pt) * 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
TR199901772T2 (pl) * 1997-02-17 1999-09-21 Byk Gulden Lomberg Chemische Fabrik Gmbh
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤

Also Published As

Publication number Publication date
CA2382886C (en) 2009-06-09
UA72541C2 (en) 2005-03-15
JP2001081031A (ja) 2001-03-27
ZA200201424B (en) 2002-11-27
PT1208086E (pt) 2006-07-31
AR025434A1 (es) 2002-11-27
BR0013648A (pt) 2002-05-07
CN1147472C (zh) 2004-04-28
DE60026144D1 (de) 2006-04-27
AU6841600A (en) 2001-03-26
WO2001016106A1 (en) 2001-03-08
PL201274B1 (pl) 2009-03-31
JP2003508386A (ja) 2003-03-04
EP1208086A1 (en) 2002-05-29
NZ517520A (en) 2003-05-30
KR100712640B1 (ko) 2007-05-02
RU2260428C2 (ru) 2005-09-20
NO20020952D0 (no) 2002-02-27
CA2382886A1 (en) 2001-03-08
EE200200097A (et) 2003-04-15
SK2612002A3 (en) 2002-09-10
SK287252B6 (sk) 2010-04-07
NO20020952L (no) 2002-03-20
US6638530B1 (en) 2003-10-28
SI1208086T1 (sl) 2006-08-31
HUP0203330A2 (hu) 2003-02-28
CN1371366A (zh) 2002-09-25
HK1046277B (zh) 2004-11-26
CZ2002724A3 (cs) 2002-07-17
HUP0203330A3 (en) 2004-03-01
ES2259289T3 (es) 2006-10-01
EE05063B1 (et) 2008-08-15
DE60026144T2 (de) 2006-11-16
TWI268778B (en) 2006-12-21
MXPA02002090A (es) 2003-08-20
HK1046277A1 (en) 2003-01-03
BG106439A (en) 2002-11-29
EP1208086B1 (en) 2006-02-22
ATE318258T1 (de) 2006-03-15
DK1208086T3 (da) 2006-06-19
HRP20020182B1 (en) 2007-08-31
KR20020023424A (ko) 2002-03-28
BG65544B1 (bg) 2008-11-28
NO322532B1 (no) 2006-10-23
AU773617B2 (en) 2004-05-27
IL148357A (en) 2006-12-10
IL148357A0 (en) 2002-09-12
HRP20020182A2 (en) 2004-02-29
CZ301737B6 (cs) 2010-06-09

Similar Documents

Publication Publication Date Title
SI1208086T1 (sl) Benzamidna formulacija s histon deacetilazno inhibitorsko aktivnostjo
EG25655A (en) Benzamide derivatives useful as histone deacetylase inhibitors
HUE036127T2 (hu) Benzamidszármazék, mint hatékony differenciáló és antiproliferációs aktivitású hiszton-deacetiláz inhibitor
AU2003219595A8 (en) Alpha,beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
PL361408A1 (pl) Pochodne hydroksamowe użyteczne jako inhibitory deacetylazy
AU2002243402A1 (en) Inhibitors of histone deacetylase
HUP0000145A3 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
IL148497A0 (en) Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
IL144214A0 (en) Benzoheterocycles and their use as mek inhibitors
HUP0402370A3 (en) Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination
PL374970A1 (pl) Podstawione kwasy tienylo-hydroksamowe jako inhibitory deacetylazy histonowej
AU2003286249A8 (en) Histone deacetylase inhibitors
IL147246A0 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
NO20012245D0 (no) Anthranilsyreamider og anvendelse derav som medikamenter
IL159097A0 (en) Aromatic hydroxamic acid derivatives useful as hdac inhibitors
AU2001298014A1 (en) Inhibition of specific histone deacetylase isoforms
AU3469199A (en) Maize histone deacetylases and their use
GB0005199D0 (en) Modulation of histone deacetylase
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
EP1408946A4 (en) HISTONE DEACETYLASE INHIBITORS
AU2002330850A1 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
AU2002215018A1 (en) Human histone deacetylase gene
AU2002361096A1 (en) Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
AU7608100A (en) 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors
IL143713A0 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20110829